Table 1 Overview of clinically approved and under clinical trials PSs
From: Clinical development of photodynamic agents and therapeutic applications
| Â | Generic name | Excitation Wavelength | Manufacturer | Application |
|---|---|---|---|---|
First generation | Clinically approved | |||
Photofrin® | 630 | Axcan Pharma, Canada | Esophageal cancer, Lung adenocarcinoma, Endobronchial cancer | |
Second generation | Ameluz®/Levulan® | 635 | DUSA, USA | Mild to moderate actinic keratosis |
Metvix®/Metvixia® | 570–670 | Galderma, UK | Non-hyperkeratotic actinic keratosis and basal cell carcinoma | |
Foscan® | 652 | Biolitec, Germany | Advanced Head and neck cancer | |
Laserphyrin® | 664 | Meiji Seika, Japan | Early centrally located lung cancer | |
Visudyne® | 690 | Novartis, Switzerland | Age-related macular degeneration | |
Redaporfin® | 749 | Luzitin, Portugal | Biliary tract cancer | |
Under clinical trails | ||||
Fotolon | 665 | Apocare Pharma, Germany | Nasopharyngeal, sarcoma | |
Radachlorin | 662 | Rada-pharma, Russia | skin cancer | |
Photochlor | 664 | Rosewell Park | Head and neck cancer | |
TOOKAD | 762 | Negma-Lerads | Prostate cancer | |
Antrin | 732 | Pharmacyclics | coronary artery disease | |
Photrex | 664 | Miravant, USA | AMD | |
Talaporfin | 664 | Meiji Seika, Japan | colorectal neoplasms, Liver metastasis | |